drugset / Trial / NCT00280618

Oxaliplatin in Unresectable Hepatocellular Carcinoma

NCT00280618 ↗

Phase 2 Completed Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary: * To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-Fluorouracil/Leucovorin Secondary: * Safety and tolerability of this regimen in these patients

Timeline

Start
2004-07
Primary completion
2006-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule — —